Precipio entered into a collaboration agreement with a NY-based academic healthcare institution to jointly develop a panel for Glioblastoma, an aggressive brain cancer based on Precipio’s HemeScreen technology.Precipio will design and develop a panel that combines a select number of genes that provide prognostic and therapeutic markers for this form of cancer. The institution will contribute patient samples for the development process, its clinical know-how and expertise of its clinicians, and it intends to be the first to use the panel clinically once the panel development is completed. Precipio’s R&D team estimates a development time of under 4 months for this assay, and a cost of less than $50,000, an unprecedented speed and development cost in this industry.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRPO:
- Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
- Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
- Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
- Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
- Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology